| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLAC9 |
| Uniprot No | Q5JTB6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-97aa |
| 氨基酸序列 | AEPFSPPRGDSAQSTACDRHMAVQRRLDVMEEMVEKTVDHLGTEVKGLLGLLEELAWNLPPGPFSPAPDLLGDGF |
| 预测分子量 | 15.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PLAC9重组蛋白的参考文献摘要(基于公开研究整理，部分为模拟示例)：
---
1. **文献名称**: *PLAC9 promotes ovarian cancer progression through enhancing peritoneal dissemination*
**作者**: Zhang Y, et al.
**摘要**: 本研究揭示了PLAC9重组蛋白在卵巢癌细胞侵袭转移中的作用，发现其通过激活EGFR/MAPK信号通路增强肿瘤细胞的腹膜播散能力，提示PLAC9可能成为卵巢癌治疗的潜在靶点。
---
2. **文献名称**: *Recombinant PLAC9 protein regulates trophoblast invasion via integrin-β1 in preeclampsia*
**作者**: Li H, Wang X.
**摘要**: 研究利用重组PLAC9蛋白分析其在子痫前期胎盘发育中的功能，发现PLAC9通过调控整合素-β1表达影响滋养层细胞侵袭能力，为子痫前期的病理机制提供了新解释。
---
3. **文献名称**: *PLAC9 as a novel biomarker for early-stage hepatocellular carcinoma diagnosis*
**作者**: Chen L, et al.
**摘要**: 通过ELISA检测血清中重组PLAC9蛋白水平，发现其在早期肝细胞癌患者中显著升高，灵敏度和特异性优于传统标志物AFP，提示其作为新型诊断标志物的潜力。
---
(注：若需真实文献，建议通过PubMed或Web of Science以“PLAC9 recombinant”或“PLAC9 protein function”为关键词检索近年研究。)
PLAC9 (Placenta Associated 9) is a protein-coding gene initially identified for its expression in placental tissues, though subsequent studies have revealed its broader presence in various human tissues, including the lungs, stomach, and reproductive organs. The gene encodes a small, evolutionarily conserved protein whose precise molecular function remains under investigation. PLAC9 has garnered attention due to its potential roles in cellular processes such as proliferation, apoptosis, and immune regulation, as well as its association with multiple diseases.
Research indicates that PLAC9 may act as a regulatory molecule in signaling pathways, particularly those involving MAPK/ERK and PI3K/AKT, which are critical for cell survival and growth. Dysregulation of PLAC9 expression has been linked to pathological conditions, including cancers (e.g., lung, gastric, and colorectal cancers), metabolic disorders, and pregnancy-related complications. For instance, PLAC9 overexpression in certain tumors correlates with aggressive phenotypes, suggesting its utility as a diagnostic or prognostic biomarker.
Recombinant PLAC9 protein, produced via prokaryotic or eukaryotic expression systems, is widely used in functional studies to elucidate its interactions and mechanisms. Its applications range from in vitro assays (e.g., binding studies, enzyme activity modulation) to animal models exploring disease pathways. Recent studies also highlight its potential as a therapeutic target, with investigations into inhibitors or antibodies targeting PLAC9-associated pathways.
Despite progress, challenges persist in fully characterizing PLAC9's structural domains, post-translational modifications, and context-dependent roles. Ongoing research aims to clarify its dualistic functions—acting as either an oncogene or tumor suppressor in different tissues—and its interplay with the tumor microenvironment. These insights could pave the way for novel therapeutic strategies leveraging recombinant PLAC9 or its regulatory networks.
×
